Literature DB >> 10816080

Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin.

P Conradt1, J Hess, S H Kaufmann.   

Abstract

Cytolytic T-cell responses from 63 normal blood donors were monitored in a Mycobacterium bovis BCG infection system in vitro. We wanted to know whether cultured dendritic cells were capable of potentiating the cytolytic T-cell responses to M. bovis BCG. Infected cultured dendritic cells were up to ten times more effective antigen-presenting cells than macrophages in proliferative assays, while cytolytic T-cell induction did not differ significantly between dendritic cells and macrophages. Separated CD4+ and CD8+ T-cell subsets contributed equally to lysis of infected targets. Experiments comparing wild-type M. bovis BCG strain with two new recombinant M. bovis BCG strains secreting listeriolysin revealed statistically significant higher maximal lysis values for recombinant M. bovis BCG. We conclude from our in vitro infection system with mycobacteria that dendritic cells are superior to macrophages in proliferative assays but equal to macrophages in their ability to induce cytolytic T-cell responses. Moreover, our data suggest that recombinant M. bovis BCG vaccine strains secreting listeriolysin improve cytolytic T-cell responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10816080     DOI: 10.1016/s1286-4579(99)80077-x

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  10 in total

1.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL).

Authors:  N Porakishvili; T Roschupkina; T Kalber; A P Jewell; K Patterson; K Yong; P M Lydyard
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

Authors:  Daniel F Hoft; Azra Blazevic; Getahun Abate; Willem A Hanekom; Gilla Kaplan; Jorge H Soler; Frank Weichold; Larry Geiter; Jerald C Sadoff; Marcus A Horwitz
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

3.  Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes.

Authors:  M Abolhassani; M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 4.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 5.  Temperature-sensitive bacterial pathogens generated by the substitution of essential genes from cold-loving bacteria: potential use as live vaccines.

Authors:  Barry N Duplantis; Catherine M Bosio; Francis E Nano
Journal:  J Mol Med (Berl)       Date:  2011-01-13       Impact factor: 5.606

Review 6.  Recombinant BCG to Enhance Its Immunomodulatory Activities.

Authors:  Magdalena Kowalewicz-Kulbat; Camille Locht
Journal:  Vaccines (Basel)       Date:  2022-05-23

7.  The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses.

Authors:  Paul D Hulseberg; Alla Zozulya; Hamlet H Chu; James A Triccas; Zsuzsanna Fabry; Matyas Sandor
Journal:  Immunol Lett       Date:  2009-12-11       Impact factor: 3.685

Review 8.  Paediatric tuberculosis.

Authors:  Sandra M Newton; Andrew J Brent; Suzanne Anderson; Elizabeth Whittaker; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

Review 9.  Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Authors:  Samuel M Behar; Joshua S M Woodworth; Ying Wu
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

Review 10.  The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Authors:  Natalie E Nieuwenhuizen; Prasad S Kulkarni; Umesh Shaligram; Mark F Cotton; Cyrill A Rentsch; Bernd Eisele; Leander Grode; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.